BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bestetti R, Theodoropoulos TA, Burdmann EA, Filho MA, Cordeiro JA, Villafanha D. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation. 2006;81:692-696. [PMID: 16534470 DOI: 10.1097/01.tp.0000177644.45192.a3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 McDonald MA, Gustafsson F, Almasood A, Barth D, Ross HJ. Sirolimus is associated with impaired hematopoiesis in heart transplant patients? A retrospective analysis. Transplant Proc 2010;42:2693-6. [PMID: 20832571 DOI: 10.1016/j.transproceed.2010.05.158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
2 Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH. Sirolimus-Based Immunosuppression After Cardiac Transplantation: Predictors of Recovery From Calcineurin Inhibitor-Induced Renal Dysfunction. The Journal of Heart and Lung Transplantation 2007;26:998-1003. [DOI: 10.1016/j.healun.2007.07.034] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
3 Raichlin E, Kushwaha SS. Proliferation signal inhibitors and cardiac allograft vasculopathy. Curr Opin Organ Transplant. 2008;13:543-550. [PMID: 19060540 DOI: 10.1097/mot.0b013e32830fdf70] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
4 Zuckermann A, Eisen H, See Tai S, Li H, Hahn C, Crespo-leiro MG. Sirolimus Conversion After Heart Transplant: Risk Factors for Acute Rejection and Predictors of Renal Function Response: Renal Function After Conversion to Sirolimus. American Journal of Transplantation 2014;14:2048-54. [DOI: 10.1111/ajt.12833] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Delgado JF, Crespo MG, Manito N, Camprecios M, Rábago G, Lage E, Arizón JM, Roig E. Usefulness of sirolimus as rescue therapy in heart transplant recipients with renal failure: analysis of the Spanish Multicenter Observational Study (RAPACOR). Transplant Proc. 2009;41:3835-3837. [PMID: 19917397 DOI: 10.1016/j.transproceed.2009.06.236] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
6 Kim IC, Youn JC, Kobashigawa JA. The Past, Present and Future of Heart Transplantation. Korean Circ J 2018;48:565-90. [PMID: 29968430 DOI: 10.4070/kcj.2018.0189] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 12.3] [Reference Citation Analysis]
7 Cantarovich M. Renal protective strategies in heart transplant patients. Current Opinion in Cardiology 2007;22:133-8. [DOI: 10.1097/hco.0b013e32801466e4] [Cited by in Crossref: 15] [Article Influence: 1.1] [Reference Citation Analysis]
8 Söderlund C, Rådegran G. Immunosuppressive therapies after heart transplantation — The balance between under- and over-immunosuppression. Transplantation Reviews 2015;29:181-9. [DOI: 10.1016/j.trre.2015.02.005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
9 Borrows R, Cockwell P. Measuring Renal Function in Solid Organ Transplant Recipients. Transplantation 2007;83:529-31. [DOI: 10.1097/01.tp.0000255566.42513.00] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
10 Gustafsson F, Ross HJ. Renal-sparing strategies in cardiac transplantation. Current Opinion in Organ Transplantation 2009;14:566-70. [DOI: 10.1097/mot.0b013e32832e6f7b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Thibodeau JT, Mishkin JD, Patel PC, Kaiser PA, Ayers CR, Mammen PPA, Markham DW, Ring WS, Peltz M, Drazner MH. Tolerability of sirolimus: a decade of experience at a single cardiac transplant center. Clin Transplant 2013;27:945-52. [DOI: 10.1111/ctr.12269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
12 Khandhar SJ, Shah HV, Shullo MA, Zomak R, Navoney M, Mcnamara DM, Kormos RL, Toyoda Y, Teuteberg JJ. Long-term effects on renal function of dose-reduced calcineurin inhibitor and sirolimus in cardiac transplant patients: Renal function after sirolimus. Clinical Transplantation 2012;26:42-9. [DOI: 10.1111/j.1399-0012.2011.01407.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ubilla M, Mastrobuoni S, Cordero A, Castaño S, Herreros J, Rábago G. Impact on Renal Function of the Use of Sirolimus in Cardiac Transplantation. Transplantation Proceedings 2007;39:2401-2. [DOI: 10.1016/j.transproceed.2007.07.060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
14 Bestetti RB, Theodoropoulos TA, Burdmann EA, Santos MA, Abbud-filho M. Switch from cyclosporine to sirolimus as a treatment of acute renal failure complicating cardiogenic shock in a heart transplant recipient. International Journal of Cardiology 2006;112:e83-4. [DOI: 10.1016/j.ijcard.2006.03.081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008;52:587-598. [PMID: 18702960 DOI: 10.1016/j.jacc.2008.05.020] [Cited by in Crossref: 140] [Cited by in F6Publishing: 92] [Article Influence: 10.8] [Reference Citation Analysis]
16 González-Vílchez F, Vázquez de Prada JA. Chronic renal insufficiency in heart transplant recipients: risk factors and management options. Drugs 2014;74:1481-94. [PMID: 25134671 DOI: 10.1007/s40265-014-0274-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Manito N, Delgado JF, Crespo-Leiro MG, González-Vílchez F, Almenar L, Arizón JM, Díaz B, Fernández-Yáñez J, Mirabet S, Palomo J, Rodríguez Lambert JL, Roig E, Segovia J. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev (Orlando) 2010;24:129-42. [PMID: 20619801 DOI: 10.1016/j.trre.2010.01.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
18 Dandel M, Lehmkuhl HB, Knosalla C, Hetzer R. Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation. Transpl Immunol 2010;23:93-103. [PMID: 20434559 DOI: 10.1016/j.trim.2010.04.007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
19 Manito N, Rábago G, Palomo J, Arizón J, Delgado J, Almenar L, Crespo-leiro M, Lage E, Pulpón L. Improvement in Chronic Renal Failure after Mycophenolate Mofetil Introduction and Cyclosporine Dose Reduction: Four-Year Results From a Cohort of Heart Transplant Recipients. Transplantation Proceedings 2011;43:2699-706. [DOI: 10.1016/j.transproceed.2011.04.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
20 Crespo-leiro MG, Hermida-prieto M. Sirolimus treatment of left ventricular hypertrophy: who, and when? European Heart Journal 2008;29:2703-4. [DOI: 10.1093/eurheartj/ehn470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Boilson BA, Raichlin E, Park SJ, Kushwaha SS. Device Therapy and Cardiac Transplantation for End-Stage Heart Failure. Current Problems in Cardiology 2010;35:8-64. [DOI: 10.1016/j.cpcardiol.2009.09.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
22 Kittleson MM, Kobashigawa JA. Cardiac Transplantation. JACC: Heart Failure 2017;5:857-68. [DOI: 10.1016/j.jchf.2017.08.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 9.8] [Reference Citation Analysis]
23 Cantarovich M, Giannetti N, Routy JP, Cecere R, Barkun J. Long-term immunosuppression with anti-CD25 monoclonal antibodies in heart transplant patients with chronic kidney disease. J Heart Lung Transplant 2009;28:912-8. [PMID: 19716044 DOI: 10.1016/j.healun.2009.05.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Zuckermann A, Keogh A, Crespo-leiro MG, Mancini D, Vilchez FG, Almenar L, Brozena S, Eisen H, Tai SS, Kushwaha S. Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal Insufficiency: Sirolimus in Cardiac Transplant Recipients. American Journal of Transplantation 2012;12:2487-97. [DOI: 10.1111/j.1600-6143.2012.04131.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
25 Fuchs U, Zittermann A, Hakim-meibodi K, Börgermann J, Schulz U, Gummert J. Everolimus Plus Dosage Reduction of Cyclosporine in Cardiac Transplant Recipients with Chronic Kidney Disease: A Two-Year Follow-up Study. Transplantation Proceedings 2011;43:1839-46. [DOI: 10.1016/j.transproceed.2010.12.055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
26 Sánchez-Fructuoso AI. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2008;4:807-19. [PMID: 18611120 DOI: 10.1517/17425255.4.6.807] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
27 Gustafsson F, Ross HJ. Proliferation signal inhibitors in cardiac transplantation. Curr Opin Cardiol. 2007;22:111-116. [PMID: 17284989 DOI: 10.1097/hco.0b013e328012545e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
28 Demirjian S, Stephany B, Abu Romeh I, Boumitri M, Yamani M, Poggio E. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients. Clinical Transplantation 2009;23:351-60. [DOI: 10.1111/j.1399-0012.2009.00963.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
29 Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol. 2008;20:32-42. [PMID: 18773960 DOI: 10.1016/j.trim.2008.08.005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
30 Thibodeau JT, Mishkin JD, Patel PC, Kaiser PA, Ayers CR, Mammen PPA, Markham DW, Ring WS, Peltz M, Drazner MH. Sirolimus use and incidence of venous thromboembolism in cardiac transplant recipients. Clin Transplant 2012;26:953-9. [DOI: 10.1111/j.1399-0012.2012.01677.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
31 Chinnock TJ, Shankel T, Deming D, Cutler D, Sahney S, Fitts J, Chinnock RE. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients: CNI minimization leads to improved renal function. Pediatric Transplantation 2011;15:746-9. [DOI: 10.1111/j.1399-3046.2011.01566.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
32 Matthews K, Gossett J, Kappelle PV, Jellen G, Pahl E. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: Intermediate experience in pediatric heart transplantation recipients. Pediatric Transplantation 2010;14:402-8. [DOI: 10.1111/j.1399-3046.2010.01306.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
33 Wagner OJ, Inglin RA, Bisch-knaden S, Mettler D, Borner M, Candinas D, Egger B. Sirolimus and intraoperative hyperthermic peritoneal chemoperfusion with mitomycin-C do not impair healing of bowel anastomoses. Transplant Int 2008;21:554-63. [DOI: 10.1111/j.1432-2277.2007.00635.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Somers MJ, Paul E. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation. The Journal of Clinical Pharmacology 2015;55:368-76. [DOI: 10.1002/jcph.428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]